Clostridium Difficile Infection: Management Strategies for a Difficult Disease

Overview

Journal Therap Adv Gastroenterol

Publisher Sage Publications

Specialty Gastroenterology

Date 2014 Mar 4

PMID 24587820

Citations 20

Authors

Sahil Khanna

Darrell S Pardi

Affiliations

Soon will be listed here.

Abstract

Clostridium difficile was first described as a cause of diarrhea in 1978 and in the last three decades has reached an epidemic state with increasing incidence and severity in both healthcare and community settings. There also has been a rise in severe outcomes from C. difficile infection (CDI). There have been tremendous advancements in the field of CDI with the identification of newer risk factors, recognition of CDI in populations previously thought not at risk and development of better diagnostic modalities. Several treatment options are available for CDI apart from metronidazole and vancomycin, and include new drugs such as fidaxomicin and other options such as fecal microbiota transplantation. This review discusses the epidemiology, risk factors and outcomes from CDI, and focuses primarily on existing and evolving treatment modalities.

Citing Articles

Outcomes of Continuous Enteral Vancomycin Infusion in Intensive Care Unit Patients: A Novel Treatment Modality for Severe Clostridium Difficile Colitis.

Peters H, Iqbal A, Miller E, Khalid S, Rahman O Cureus. 2022; 14(3):e22872.

PMID: 35392442 PMC: 8979637. DOI: 10.7759/cureus.22872.

Multi-Strain Probiotics: Synergy among Isolates Enhances Biological Activities.

Kwoji I, Aiyegoro O, Okpeku M, Adeleke M Biology (Basel). 2021; 10(4).

PMID: 33924344 PMC: 8070017. DOI: 10.3390/biology10040322.

co-infection with Enterohemorrhagic (EHEC)-a potentially fatal combination.

Deshmukh F, Agrawal U, Merrell N IDCases. 2020; 21:e00797.

PMID: 32489867 PMC: 7256656. DOI: 10.1016/j.idcr.2020.e00797.

Real-world Experience of Bezlotoxumab for Prevention of Infection: A Retrospective Multicenter Cohort Study.

Hengel R, Ritter T, Nathan R, Van Anglen L, Schroeder C, Dillon R Open Forum Infect Dis. 2020; 7(4):ofaa097.

PMID: 32363211 PMC: 7186524. DOI: 10.1093/ofid/ofaa097.

Cytoskeletal Tropomyosin as a Biomarker in Infection.

Usacheva E, Peterson L, Mendoza K, Schora D, Hossain M, Jin J J Clin Med Res. 2019; 11(2):98-105.

PMID: 30701001 PMC: 6340674. DOI: 10.14740/jocmr3696.

References

Khanna S, Pardi D, Rosenblatt J, Patel R, Kammer P, Baddour L . An evaluation of repeat stool testing for Clostridium difficile infection by polymerase chain reaction. J Clin Gastroenterol. 2012; 46(10):846-9. DOI: 10.1097/MCG.0b013e3182432273. View

Allen S, Wareham K, Wang D, Bradley C, Hutchings H, Harris W . Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2013; 382(9900):1249-57. DOI: 10.1016/S0140-6736(13)61218-0. View

Kelly C, Lamont J . Clostridium difficile--more difficult than ever. N Engl J Med. 2008; 359(18):1932-40. DOI: 10.1056/NEJMra0707500. View

Khanna S, Baddour L, Huskins W, Kammer P, Faubion W, Zinsmeister A . The epidemiology of Clostridium difficile infection in children: a population-based study. Clin Infect Dis. 2013; 56(10):1401-6. PMC: 3693491. DOI: 10.1093/cid/cit075. View

Cornely O, Crook D, Esposito R, Poirier A, Somero M, Weiss K . Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2012; 12(4):281-9. DOI: 10.1016/S1473-3099(11)70374-7. View

Keddis M, Khanna S, Noheria A, Baddour L, Pardi D, Qian Q . Clostridium difficile infection in patients with chronic kidney disease. Mayo Clin Proc. 2012; 87(11):1046-53. PMC: 3541867. DOI: 10.1016/j.mayocp.2012.05.025. View

Khanna S, Pardi D . Gastric acid suppression and Clostridium difficile infection: is there a causal connection?. Clin Gastroenterol Hepatol. 2012; 10(5):564. DOI: 10.1016/j.cgh.2012.01.013. View

Khanna S, Keddis M, Noheria A, Baddour L, Pardi D . Acute kidney injury is an independent marker of severity in Clostridium difficile infection: a nationwide survey. J Clin Gastroenterol. 2012; 47(6):481-4. DOI: 10.1097/MCG.0b013e31826af6fd. View

Zilberberg M, Shorr A, Kollef M . Increase in Clostridium difficile-related hospitalizations among infants in the United States, 2000-2005. Pediatr Infect Dis J. 2008; 27(12):1111-3. DOI: 10.1097/inf.0b013e31817eef13. View

10.

Im G, Modayil R, Lin C, Geier S, Katz D, Feuerman M . The appendix may protect against Clostridium difficile recurrence. Clin Gastroenterol Hepatol. 2011; 9(12):1072-7. DOI: 10.1016/j.cgh.2011.06.006. View

11.

Linsky A, Gupta K, Lawler E, Fonda J, Hermos J . Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med. 2010; 170(9):772-8. DOI: 10.1001/archinternmed.2010.73. View

12.

Rao A, Jump R, Pultz N, Pultz M, Donskey C . In vitro killing of nosocomial pathogens by acid and acidified nitrite. Antimicrob Agents Chemother. 2006; 50(11):3901-4. PMC: 1635176. DOI: 10.1128/AAC.01506-05. View

13.

Surawicz C, Brandt L, Binion D, Ananthakrishnan A, Curry S, Gilligan P . Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013; 108(4):478-98. DOI: 10.1038/ajg.2013.4. View

14.

Leav B, Blair B, Leney M, Knauber M, Reilly C, Lowy I . Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine. 2009; 28(4):965-9. DOI: 10.1016/j.vaccine.2009.10.144. View

15.

Johnson S, Schriever C, Galang M, Kelly C, Gerding D . Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis. 2007; 44(6):846-8. DOI: 10.1086/511870. View

16.

Abougergi M, Kwon J . Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review. Dig Dis Sci. 2010; 56(1):19-26. DOI: 10.1007/s10620-010-1411-2. View

17.

Brandt L, Aroniadis O . An overview of fecal microbiota transplantation: techniques, indications, and outcomes. Gastrointest Endosc. 2013; 78(2):240-9. DOI: 10.1016/j.gie.2013.03.1329. View

18.

Musher D, Aslam S, Logan N, Nallacheru S, Bhaila I, Borchert F . Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis. 2005; 40(11):1586-90. DOI: 10.1086/430311. View

19.

Belmares J, Gerding D, Parada J, Miskevics S, Weaver F, Johnson S . Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system. J Infect. 2007; 55(6):495-501. DOI: 10.1016/j.jinf.2007.09.015. View

20.

Carroll K . Tests for the diagnosis of Clostridium difficile infection: the next generation. Anaerobe. 2011; 17(4):170-4. DOI: 10.1016/j.anaerobe.2011.01.002. View